Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules

Int J Cardiol. 2010 Mar 4;139(2):150-8. doi: 10.1016/j.ijcard.2008.10.010. Epub 2008 Nov 11.

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) exert cardioprotective effects. We examined whether SSRIs a) modulate endothelial cell expression of vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1) and adhesiveness to U937 monocytes, b) reduce the circulating levels of these adhesion molecules in vivo.

Methods: We assessed the effect of SSRIs, (citalopram, fluvoxamine and fluoxetine), on TNF-alpha-induced expression of VCAM-1 and ICAM-1 in human aorta endothelial cells and adhesiveness to U937 monocytes. Cells were incubated with TNF-alpha in the absence and in the presence of SSRIs concentrations from 10(-7) M to10(-4) M and the VCAM-1 and ICAM-1 expression was quantified by cell-ELISA. The TNF-alpha-stimulated adhesiveness to U937 monocytes was also assessed. Twenty five patients with chronic heart failure and depression were randomized to receive sertaline 50 mg, p.o., o.d. (n=13) or placebo. At baseline and 3-months after treatment, we measured VCAM-1 and ICAM-1 plasma levels.

Results: SSRIs decreased the TNF-alpha-induced endothelial expression of VCAM-1 at concentration range 10(-7) M to 10(-4) M (p<0.05). ICAM-1 expression was decreased in the presence of fluvoxamine and fluoxetine at concentrations from 10(-7) M to 10(-4) M (p<0.05) and in the presence of citalopram at concentrations from 10(-7) M to 10(-5) M (p<0.05). All SSRIs inhibited the TNF-alpha-stimulated adhesiveness to U937 cells at 10(-5) M and 10(-4) M (p<0.05). Compared to baseline, there was a greater reduction in ICAM-1 and VCAM-1 levels post-sertaline than post placebo in heart failure patients (p<0.05).

Conclusion: SSRIs may exhibit an anti-inflammatory activity on endothelial cells and reduce circulating VCAM-1 and ICAM-1 in vivo, a mechanism which may partly mediate their cardioprotective effects.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aorta / cytology
  • Cell Adhesion / drug effects*
  • Cell Survival / drug effects
  • Chronic Disease
  • Citalopram / pharmacology
  • Depression / complications
  • Depression / drug therapy
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects*
  • Enzyme-Linked Immunosorbent Assay
  • Fluoxetine / pharmacology
  • Fluvoxamine / pharmacology
  • Heart Failure / complications
  • Heart Failure / pathology
  • Humans
  • Intercellular Adhesion Molecule-1 / blood
  • Middle Aged
  • Monocytes / cytology
  • Monocytes / drug effects*
  • Placebos
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Sertraline / therapeutic use*
  • Tumor Necrosis Factor-alpha / pharmacology
  • U937 Cells
  • Vascular Cell Adhesion Molecule-1 / blood

Substances

  • Placebos
  • Serotonin Uptake Inhibitors
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • Fluoxetine
  • Citalopram
  • Intercellular Adhesion Molecule-1
  • Fluvoxamine
  • Sertraline